- Home
- TRMK vs IBRX Comparison
TRMK vs IBRX Comparison
Compare TRMK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMK
- IBRX
- Stock Information
- Founded
- TRMK 1889
- IBRX 2014
- Country
- TRMK United States
- IBRX United States
- Employees
- TRMK N/A
- IBRX N/A
- Industry
- TRMK Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRMK Finance
- IBRX Health Care
- Exchange
- TRMK Nasdaq
- IBRX Nasdaq
- Market Cap
- TRMK 2.4B
- IBRX 2.3B
- IPO Year
- TRMK 1987
- IBRX N/A
- Fundamental
- Price
- TRMK $39.77
- IBRX $2.76
- Analyst Decision
- TRMK Buy
- IBRX Strong Buy
- Analyst Count
- TRMK 4
- IBRX 6
- Target Price
- TRMK $41.00
- IBRX $9.83
- AVG Volume (30 Days)
- TRMK 230.6K
- IBRX 9.7M
- Earning Date
- TRMK 10-21-2025
- IBRX 11-11-2025
- Dividend Yield
- TRMK 2.43%
- IBRX N/A
- EPS Growth
- TRMK 17.82
- IBRX N/A
- EPS
- TRMK 3.56
- IBRX N/A
- Revenue
- TRMK $758,379,000.00
- IBRX $56,600,000.00
- Revenue This Year
- TRMK $58.78
- IBRX $629.94
- Revenue Next Year
- TRMK $4.52
- IBRX $109.91
- P/E Ratio
- TRMK $11.08
- IBRX N/A
- Revenue Growth
- TRMK 58.50
- IBRX 4227.22
- 52 Week Low
- TRMK $29.77
- IBRX $1.83
- 52 Week High
- TRMK $41.34
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- TRMK 52.50
- IBRX 64.62
- Support Level
- TRMK $39.08
- IBRX $2.32
- Resistance Level
- TRMK $40.47
- IBRX $2.67
- Average True Range (ATR)
- TRMK 0.71
- IBRX 0.14
- MACD
- TRMK -0.16
- IBRX 0.05
- Stochastic Oscillator
- TRMK 30.53
- IBRX 72.73
About TRMK Trustmark Corporation
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.